AstraZeneca's COVID-19 vaccine closer to UK market despite reports of new trial

27 November 2020

It has been a long and confusing week for investors and patients trying to work out what is going on with the COVID-19 vaccine being developed by the University of Oxford and Anglo-Swedish drugmaker AstraZeneca (LSE: AZN).

Monday’s positive high-level data on AZD1222 was billed as a third set of encouraging clinical results this month on coronavirus vaccines, following first Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX), and then Moderna (Nasdaq: MRNA).

But markets were unsure, with confusion over why a lower dosing regimen showed vaccine efficacy of 90%, while another showed 62%. The overall efficacy figure was 70%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK